EU Clears First Subcutaneous Immunoglobulin (Hizentra) for CIDP EU Clears First Subcutaneous Immunoglobulin (Hizentra) for CIDP

Hizentra is the first subcutaneous immunoglobulin approved as maintenance therapy to prevent relapse of neuromuscular disability and impairment in chronic inflammatory demyelinating polyneuropathy.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news